IRA im­pact on bio­phar­ma: Lat­est dis­clo­sures range from un­known to neg­a­tive

Drug­mak­ers are at­tempt­ing to de­tail how they ex­pect Medicare’s drug price “ne­go­ti­a­tions” (a term now co-opt­ed by the bio­phar­ma in­dus­try as “price set­ting”) to im­pact …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER